How the Dow's Pharma Stocks Have Fared in 2013

The Dow Jones Industrial Average (DJINDICES: ^DJI  ) isn't just for industrial stocks anymore. You can find all sorts of companies in the venerable average, with the Dow representing a nearly all-inclusive cross-section of the entire U.S. economy.

Pharma stocks aren't a huge part of the Dow, with just two of its constituents focused solely on the space and a third reaping a substantial portion of its revenue from pharmaceuticals. Yet pharma stocks have made a big impression on investors because of their lucrative dividend yields. Let's take a look at how these companies have fared so far in 2013 and what their prospects are for the rest of the year and beyond.

JNJ Total Return Price Chart

JNJ Total Return Price data by YCharts.

You may not think of Johnson & Johnson (NYSE: JNJ  ) as a pharmaceutical company, as it's far better-known for its consumer products. But the health care conglomerate also produces proprietary drugs and medical devices, giving it a broad reach over the entire health care industry. Lately, even as the company has faced liability from recalls of its artificial hip replacements, Johnson & Johnson has gotten help from its pharma division, as the approval of its type 2 diabetes drug Invokana represents a big step forward in diabetes treatment that could produce the company's next blockbuster.

Meanwhile, pure pharma stocks Pfizer (NYSE: PFE  ) and Merck (NYSE: MRK  ) have both dealt with patent expirations of high-profile drugs over the past couple of years, including Merck's Singulair and Pfizer's Lipitor. Yet while revenue has predictably fallen since generic competition hit the market, both companies have held up better than pessimists had expected.

For Pfizer, anticlotting drug Eliquis, which it co-developed with Bristol-Myers Squibb, has the potential to generate billions in sales over the next decade, having several advantages over rival drugs designed to replace the existing warfarin treatment for atrial fibrillation. Merck still faces some patent-cliff problems, with Vytorin, Nasonex, and Zetia coming off patent over the next four years. But with the combination of existing diabetes drugs Januvia and Janumet and up-and-coming development-stage drugs like insomnia treatment suvorexant and osteoporosis drug odanacatib, Merck has good prospects looking forward.

Keep looking for healthy results
With the pharma industry having turned the patent-cliff corner, pharma stocks should continue contributing to the Dow's overall success. Given the emphasis on dividend income, the big yields that Pfizer and Merck pay will likely remain big drawing points for years to come.

As big as Johnson & Johnson is in health care, some critics are convinced that the company is spread too thin. Is Johnson & Johnson overextended, or is it a well-diversified health-care giant that deserves a place in your portfolio? Find out our view by checking out the Fool's new premium report. Inside, our analyst outlines the Johnson & Johnson story in terms that any investor can understand. Claim your copy by clicking here now


Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2355364, ~/Articles/ArticleHandler.aspx, 12/21/2014 6:32:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement